Zymeworks Inc (ZYME) - News Archive

Paving the Path in Oncology: Zymeworks Sets the Stage for Medical Breakthroughs at Premier Global Conferences In an inspiring move set to influence the oncology landscape significantly, Zymeworks Inc. (Nasdaq: ZYME) is...

Potential Therapeutic Advances: Preclinical Insights into ZW1528, a Novel IL4R x IL33 Bispecific Molecule for Respiratory Inflammation Biotherapeutics have revolutionized the treatment landscape for numerous diseases, o...

Vancouver, British Columbia—In a press release dated January 8, 2025, Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology firm, articulated its strategic priorities and outlook for the years 2025 and 2026. The...

Zymeworks Inc. a leading biotechnology firm focused on innovative biotherapeutics, has recently made significant strides in the development of ZW191, a novel folate receptor (FR)-targeted topoisomerase I inhibitor antib...

Zymeworks Inc. Poised to Reveal Robust Q3 2024 Financial Results Amid Positive Market Performance As the frequencies of innovation and adaptation reverberate throughout the biotechnology sector, Zymeworks Inc. (Nasdaq:...

Zymeworks Inc. Reports Equity Inducement Award for Executive VP and CFO Leone PattersonIn the world of biotechnology and pharmaceuticals, the race to develop innovative therapies for difficult-to-treat diseases is alway...

Zymeworks Inc. Poised for Strategic Engagement at Prominent Investor Conferences Vancouver, British Columbia, August 22, 2024 - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company at the frontier of de...

Zymeworks Announces $30 Million Share Repurchase Program: A Boost for Shareholders Amidst Growth and Market VolatilityIn a strategic move aimed at enhancing shareholder value, Zymeworks Inc has announced its intention t...

Zymeworks Inc., a clinical-stage biotechnology company dedicated to enhancing the standard of care for challenging diseases, has achieved a significant milestone with the clearance of its investigational new drug (IND)...

Zymeworks Achieves Key Milestones in Global Development: NMPA Acceptance of BLA for Zanidatamab in China and Inclusion in Nasdaq Biotechnology Index VANCOUVER, British Columbia, June 10, 2024 Zymeworks Inc. (Nasdaq: ZYM...

Zymeworks Inc., a leading biopharmaceutical company, is currently under investigation by Pomerantz Law Firm following alleged claims made by investors. This article aims to provide an in-depth analysis of the potential...

The pharmaceutical industry is witnessing a rapid advancement in the development of innovative biotherapeutics to tackle challenging diseases. Zymeworks Inc., a pioneering biotechnology company, has recently announced t...

In a recent update, Zymeworks Inc., a clinical-stage biotechnology company, has outlined its strategic priorities for 2024 and 2025. This forward-thinking approach aims to revolutionize the standard of care for challeng...

Zymeworks Inc., a clinical-stage biotechnology company focused on developing innovative biotherapeutics, has recently announced its expected inclusion in the highly esteemed Nasdaq Biotechnology Index (NBI). This develo...